DeepMed Research

SEIKAGAKU CORPORATION

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.seikagaku.co.jp/

Clinical Trials

A Study for Evaluation of the Efficacy and Safety of SI-614 Ophthalmic Solution in Patient With Dry Eye

Phase 3

Completed

Conditions: Dry Eye Disease

Interventions: Drug: SI-614
Drug: Vehicle

First Posted Date: 2022-06-09

Last Posted Date: 2024-03-04

Lead Sponsor: Seikagaku Corporation

Target Recruit Count: 232

Registration Number: NCT05411367

Locations: 🇺🇸
Eye Research Foundation, Newport Beach, California, United States
🇺🇸
Andover Eye Associates, Inc., Andover, Massachusetts, United States
🇺🇸
CORE Inc, Vita Eye Clinic, Shelby, North Carolina, United States

and more 3 locations

PK and Safety of SI-722 in IC/BPS

Phase 1

Completed

Conditions: Interstitial Cystitis
Bladder Pain Syndrome

Interventions: Drug: Placebo
Drug: SI-722

First Posted Date: 2019-12-23

Last Posted Date: 2023-12-29

Lead Sponsor: Seikagaku Corporation

Target Recruit Count: 33

Registration Number: NCT04208087

Locations: 🇺🇸
TriValley Urology Medical Group, Murrieta, California, United States
🇺🇸
Premier Medical Associates, The Villages, Florida, United States
🇺🇸
American Institute of Research, Los Angeles, California, United States

and more 2 locations

SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study)

Phase 3

Completed

Conditions: Lumbar Disc Herniation

Interventions: Drug: SI-6603
Drug: Sham injection

First Posted Date: 2018-07-31

Last Posted Date: 2024-04-18

Lead Sponsor: Seikagaku Corporation

Target Recruit Count: 352

Registration Number: NCT03607838

Locations: 🇺🇸
Indiana Spine Group, Carmel, Indiana, United States
🇺🇸
HRMD Research, Dallas, Texas, United States
🇺🇸
Gershon Pain Specialists, Virginia Beach, Virginia, United States

and more 62 locations

SI-613 Study for Knee Osteoarthritis

Phase 2

Completed

Conditions: Osteoarthritis, Knee

Interventions: Combination Product: Placebo
Combination Product: SI-613

First Posted Date: 2017-07-06

Last Posted Date: 2021-11-04

Lead Sponsor: Seikagaku Corporation

Target Recruit Count: 80

Registration Number: NCT03209362

Locations: 🇺🇸
MM Medical Center, Inc., Miami, Florida, United States
🇺🇸
Heartland Research Associates, LLC, Newton, Kansas, United States
🇺🇸
Sundance Clinical Research, LLC, Saint Louis, Missouri, United States

and more 7 locations

A Study of SI-6603 in Patients With Lumbar Disc Herniation

Phase 3

Completed

Conditions: Intervertebral Disc Disease
Lumbar Disc Disease

Interventions: Drug: Condoliase

First Posted Date: 2015-04-20

Last Posted Date: 2023-03-23

Lead Sponsor: Seikagaku Corporation

Target Recruit Count: 1011

Registration Number: NCT02421601

A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye.

Phase 2

Completed

Conditions: Dry Eye Syndromes

Interventions: Drug: SI-614
Drug: Vehicle

First Posted Date: 2014-07-31

Last Posted Date: 2023-07-12

Lead Sponsor: Seikagaku Corporation

Target Recruit Count: 240

Registration Number: NCT02205840

A Study of SI-6603 in Patients With Lumbar Disc Herniation

Phase 3

Completed

Conditions: Intervertebral Disc Disease
Lumbar Disc Disease

Interventions: Drug: Condoliase
Drug: placebo

First Posted Date: 2013-09-13

Last Posted Date: 2023-03-23

Lead Sponsor: Seikagaku Corporation

Target Recruit Count: 385

Registration Number: NCT01941563

Gel-One Treatment in Knee Osteoarthritis

Not Applicable

Completed

Conditions: Osteoarthritis Knee

Interventions: Device: Gel-One
Device: PBS

First Posted Date: 2013-09-04

Last Posted Date: 2023-03-23

Lead Sponsor: Seikagaku Corporation

Target Recruit Count: 814

Registration Number: NCT01934218

A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye

Phase 2

Completed

Conditions: Dry Eye Syndromes

Interventions: Drug: Low concentration SI-614
Drug: Vehicle
Drug: High concentration SI-614

First Posted Date: 2012-03-20

Last Posted Date: 2023-05-11

Lead Sponsor: Seikagaku Corporation

Target Recruit Count: 150

Registration Number: NCT01558999

Locations: 🇺🇸
SKK Investigational Site, Andover, Massachusetts, United States

Clinical Trial to Assess Safety of SI-6603 in Patients With Lumbar Disc Herniation

Phase 2

Completed

Conditions: Lumbar Vertebra Hernia

Interventions: Drug: SI-6603

First Posted Date: 2011-01-25

Last Posted Date: 2023-03-23

Lead Sponsor: Seikagaku Corporation

Target Recruit Count: 18

Registration Number: NCT01282606

Locations: 🇺🇸
SKK, Encinitas, California, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy